Loading…
Crossing the HLA barriers
Studies in mice and humans demonstrate that transplantation of hematopoietic progenitors in numbers larger than commonly used (“megadose” transplants) overcomes major genetic barriers. In vitro studies suggest that veto cells, within the population of hematopoietic progenitors, facilitate this favor...
Saved in:
Published in: | Blood cells, molecules, & diseases molecules, & diseases, 2004-11, Vol.33 (3), p.206-210 |
---|---|
Main Authors: | , , , , |
Format: | Article |
Language: | English |
Subjects: | |
Citations: | Items that this one cites Items that cite this one |
Online Access: | Get full text |
Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
cited_by | cdi_FETCH-LOGICAL-c352t-eb46f92c6d00e8ec558ca08404ae5347c97045725fc5085af2d0226d93dbbadc3 |
---|---|
cites | cdi_FETCH-LOGICAL-c352t-eb46f92c6d00e8ec558ca08404ae5347c97045725fc5085af2d0226d93dbbadc3 |
container_end_page | 210 |
container_issue | 3 |
container_start_page | 206 |
container_title | Blood cells, molecules, & diseases |
container_volume | 33 |
creator | Reisner, Yair Gur, Hilit Reich-Zeliger, Shlomit Martelli, Massimo F. Bachar-Lustig, Esther |
description | Studies in mice and humans demonstrate that transplantation of hematopoietic progenitors in numbers larger than commonly used (“megadose” transplants) overcomes major genetic barriers. In vitro studies suggest that veto cells, within the population of hematopoietic progenitors, facilitate this favorable outcome. Thus, when purified CD34
+ cells were added to bulk mixed-lymphocyte reactions (MLRs), they suppressed CTLs against donor's stimulators but not against stimulators from a third party. This tolerizing activity depends on cell contact and can be blocked by the caspase inhibitor BD-FMK, suggesting that the effector host T cells are deleted by apoptosis upon interaction with the CD34
+ cells. Early myeloid CD33
+ cells generated by short-term ex vivo expansion of CD34
+ cells also exhibit veto activity, and these cells can be grown in large numbers. Tolerance induction can be further enhanced by other veto cells. Perhaps the most potent veto cell is the CD8
+ CTL. However, this cell is also associated with marked graft-versus-host disease (GVHD). GVHD can be separated from the veto activity by generating anti-third party CTLs under IL2 deprivation. Under such selective pressure, only the stimulated clones which make IL2 can survive, while anti-host clones die. In vivo studies show that such anti-third party veto CTLs can be used safely for tolerance induction without GVHD. |
doi_str_mv | 10.1016/j.bcmd.2004.08.004 |
format | article |
fullrecord | <record><control><sourceid>proquest_cross</sourceid><recordid>TN_cdi_proquest_miscellaneous_67044312</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><els_id>S1079979604001627</els_id><sourcerecordid>67044312</sourcerecordid><originalsourceid>FETCH-LOGICAL-c352t-eb46f92c6d00e8ec558ca08404ae5347c97045725fc5085af2d0226d93dbbadc3</originalsourceid><addsrcrecordid>eNp9kDFPwzAQhS0EoqXwA2BAndgSzo6d2BJLVQFFqsQCs-XYF3DVNMVOkPj3OGolNobTu-G9p7uPkBsKOQVa3m_y2rYuZwA8B5knOSFTCqrM0tDTca9UpipVTshFjBsAoFTJczKhQjBJCzYl18vQxeh3H_P-E-er9WJemxA8hnhJzhqzjXh11Bl5f3p8W66y9evzy3KxzmwhWJ9hzctGMVs6AJRohZDWgOTADYqCV1ZVwEXFRGMFSGEa5oCx0qnC1bVxtpiRu0PvPnRfA8Zetz5a3G7NDrsh6jLleUFZMrKD0Y4nB2z0PvjWhB9NQY9A9EaPQPQIRIPUSVLo9tg-1C26v8iRQDI8HAyYfvxOj-toPe4sOh_Q9tp1_r_-X-USbw4</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>67044312</pqid></control><display><type>article</type><title>Crossing the HLA barriers</title><source>ScienceDirect Journals</source><creator>Reisner, Yair ; Gur, Hilit ; Reich-Zeliger, Shlomit ; Martelli, Massimo F. ; Bachar-Lustig, Esther</creator><creatorcontrib>Reisner, Yair ; Gur, Hilit ; Reich-Zeliger, Shlomit ; Martelli, Massimo F. ; Bachar-Lustig, Esther</creatorcontrib><description>Studies in mice and humans demonstrate that transplantation of hematopoietic progenitors in numbers larger than commonly used (“megadose” transplants) overcomes major genetic barriers. In vitro studies suggest that veto cells, within the population of hematopoietic progenitors, facilitate this favorable outcome. Thus, when purified CD34
+ cells were added to bulk mixed-lymphocyte reactions (MLRs), they suppressed CTLs against donor's stimulators but not against stimulators from a third party. This tolerizing activity depends on cell contact and can be blocked by the caspase inhibitor BD-FMK, suggesting that the effector host T cells are deleted by apoptosis upon interaction with the CD34
+ cells. Early myeloid CD33
+ cells generated by short-term ex vivo expansion of CD34
+ cells also exhibit veto activity, and these cells can be grown in large numbers. Tolerance induction can be further enhanced by other veto cells. Perhaps the most potent veto cell is the CD8
+ CTL. However, this cell is also associated with marked graft-versus-host disease (GVHD). GVHD can be separated from the veto activity by generating anti-third party CTLs under IL2 deprivation. Under such selective pressure, only the stimulated clones which make IL2 can survive, while anti-host clones die. In vivo studies show that such anti-third party veto CTLs can be used safely for tolerance induction without GVHD.</description><identifier>ISSN: 1079-9796</identifier><identifier>EISSN: 1096-0961</identifier><identifier>DOI: 10.1016/j.bcmd.2004.08.004</identifier><identifier>PMID: 15528132</identifier><language>eng</language><publisher>United States: Elsevier Inc</publisher><subject>Animals ; Antigens, CD34 - immunology ; Bone marrow ; Graft vs Host Disease - immunology ; Hematopoietic Stem Cell Transplantation ; Histocompatibility - immunology ; HLA Antigens - immunology ; Humans ; Mice ; Nonmyeloablative conditioning ; T-Lymphocytes, Cytotoxic - immunology ; Tolerance ; Transplantation Immunology</subject><ispartof>Blood cells, molecules, & diseases, 2004-11, Vol.33 (3), p.206-210</ispartof><rights>2004 Elsevier Inc.</rights><lds50>peer_reviewed</lds50><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c352t-eb46f92c6d00e8ec558ca08404ae5347c97045725fc5085af2d0226d93dbbadc3</citedby><cites>FETCH-LOGICAL-c352t-eb46f92c6d00e8ec558ca08404ae5347c97045725fc5085af2d0226d93dbbadc3</cites></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><link.rule.ids>314,780,784,27924,27925</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/15528132$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Reisner, Yair</creatorcontrib><creatorcontrib>Gur, Hilit</creatorcontrib><creatorcontrib>Reich-Zeliger, Shlomit</creatorcontrib><creatorcontrib>Martelli, Massimo F.</creatorcontrib><creatorcontrib>Bachar-Lustig, Esther</creatorcontrib><title>Crossing the HLA barriers</title><title>Blood cells, molecules, & diseases</title><addtitle>Blood Cells Mol Dis</addtitle><description>Studies in mice and humans demonstrate that transplantation of hematopoietic progenitors in numbers larger than commonly used (“megadose” transplants) overcomes major genetic barriers. In vitro studies suggest that veto cells, within the population of hematopoietic progenitors, facilitate this favorable outcome. Thus, when purified CD34
+ cells were added to bulk mixed-lymphocyte reactions (MLRs), they suppressed CTLs against donor's stimulators but not against stimulators from a third party. This tolerizing activity depends on cell contact and can be blocked by the caspase inhibitor BD-FMK, suggesting that the effector host T cells are deleted by apoptosis upon interaction with the CD34
+ cells. Early myeloid CD33
+ cells generated by short-term ex vivo expansion of CD34
+ cells also exhibit veto activity, and these cells can be grown in large numbers. Tolerance induction can be further enhanced by other veto cells. Perhaps the most potent veto cell is the CD8
+ CTL. However, this cell is also associated with marked graft-versus-host disease (GVHD). GVHD can be separated from the veto activity by generating anti-third party CTLs under IL2 deprivation. Under such selective pressure, only the stimulated clones which make IL2 can survive, while anti-host clones die. In vivo studies show that such anti-third party veto CTLs can be used safely for tolerance induction without GVHD.</description><subject>Animals</subject><subject>Antigens, CD34 - immunology</subject><subject>Bone marrow</subject><subject>Graft vs Host Disease - immunology</subject><subject>Hematopoietic Stem Cell Transplantation</subject><subject>Histocompatibility - immunology</subject><subject>HLA Antigens - immunology</subject><subject>Humans</subject><subject>Mice</subject><subject>Nonmyeloablative conditioning</subject><subject>T-Lymphocytes, Cytotoxic - immunology</subject><subject>Tolerance</subject><subject>Transplantation Immunology</subject><issn>1079-9796</issn><issn>1096-0961</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2004</creationdate><recordtype>article</recordtype><recordid>eNp9kDFPwzAQhS0EoqXwA2BAndgSzo6d2BJLVQFFqsQCs-XYF3DVNMVOkPj3OGolNobTu-G9p7uPkBsKOQVa3m_y2rYuZwA8B5knOSFTCqrM0tDTca9UpipVTshFjBsAoFTJczKhQjBJCzYl18vQxeh3H_P-E-er9WJemxA8hnhJzhqzjXh11Bl5f3p8W66y9evzy3KxzmwhWJ9hzctGMVs6AJRohZDWgOTADYqCV1ZVwEXFRGMFSGEa5oCx0qnC1bVxtpiRu0PvPnRfA8Zetz5a3G7NDrsh6jLleUFZMrKD0Y4nB2z0PvjWhB9NQY9A9EaPQPQIRIPUSVLo9tg-1C26v8iRQDI8HAyYfvxOj-toPe4sOh_Q9tp1_r_-X-USbw4</recordid><startdate>20041101</startdate><enddate>20041101</enddate><creator>Reisner, Yair</creator><creator>Gur, Hilit</creator><creator>Reich-Zeliger, Shlomit</creator><creator>Martelli, Massimo F.</creator><creator>Bachar-Lustig, Esther</creator><general>Elsevier Inc</general><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>7X8</scope></search><sort><creationdate>20041101</creationdate><title>Crossing the HLA barriers</title><author>Reisner, Yair ; Gur, Hilit ; Reich-Zeliger, Shlomit ; Martelli, Massimo F. ; Bachar-Lustig, Esther</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c352t-eb46f92c6d00e8ec558ca08404ae5347c97045725fc5085af2d0226d93dbbadc3</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2004</creationdate><topic>Animals</topic><topic>Antigens, CD34 - immunology</topic><topic>Bone marrow</topic><topic>Graft vs Host Disease - immunology</topic><topic>Hematopoietic Stem Cell Transplantation</topic><topic>Histocompatibility - immunology</topic><topic>HLA Antigens - immunology</topic><topic>Humans</topic><topic>Mice</topic><topic>Nonmyeloablative conditioning</topic><topic>T-Lymphocytes, Cytotoxic - immunology</topic><topic>Tolerance</topic><topic>Transplantation Immunology</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Reisner, Yair</creatorcontrib><creatorcontrib>Gur, Hilit</creatorcontrib><creatorcontrib>Reich-Zeliger, Shlomit</creatorcontrib><creatorcontrib>Martelli, Massimo F.</creatorcontrib><creatorcontrib>Bachar-Lustig, Esther</creatorcontrib><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>MEDLINE - Academic</collection><jtitle>Blood cells, molecules, & diseases</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Reisner, Yair</au><au>Gur, Hilit</au><au>Reich-Zeliger, Shlomit</au><au>Martelli, Massimo F.</au><au>Bachar-Lustig, Esther</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Crossing the HLA barriers</atitle><jtitle>Blood cells, molecules, & diseases</jtitle><addtitle>Blood Cells Mol Dis</addtitle><date>2004-11-01</date><risdate>2004</risdate><volume>33</volume><issue>3</issue><spage>206</spage><epage>210</epage><pages>206-210</pages><issn>1079-9796</issn><eissn>1096-0961</eissn><abstract>Studies in mice and humans demonstrate that transplantation of hematopoietic progenitors in numbers larger than commonly used (“megadose” transplants) overcomes major genetic barriers. In vitro studies suggest that veto cells, within the population of hematopoietic progenitors, facilitate this favorable outcome. Thus, when purified CD34
+ cells were added to bulk mixed-lymphocyte reactions (MLRs), they suppressed CTLs against donor's stimulators but not against stimulators from a third party. This tolerizing activity depends on cell contact and can be blocked by the caspase inhibitor BD-FMK, suggesting that the effector host T cells are deleted by apoptosis upon interaction with the CD34
+ cells. Early myeloid CD33
+ cells generated by short-term ex vivo expansion of CD34
+ cells also exhibit veto activity, and these cells can be grown in large numbers. Tolerance induction can be further enhanced by other veto cells. Perhaps the most potent veto cell is the CD8
+ CTL. However, this cell is also associated with marked graft-versus-host disease (GVHD). GVHD can be separated from the veto activity by generating anti-third party CTLs under IL2 deprivation. Under such selective pressure, only the stimulated clones which make IL2 can survive, while anti-host clones die. In vivo studies show that such anti-third party veto CTLs can be used safely for tolerance induction without GVHD.</abstract><cop>United States</cop><pub>Elsevier Inc</pub><pmid>15528132</pmid><doi>10.1016/j.bcmd.2004.08.004</doi><tpages>5</tpages></addata></record> |
fulltext | fulltext |
identifier | ISSN: 1079-9796 |
ispartof | Blood cells, molecules, & diseases, 2004-11, Vol.33 (3), p.206-210 |
issn | 1079-9796 1096-0961 |
language | eng |
recordid | cdi_proquest_miscellaneous_67044312 |
source | ScienceDirect Journals |
subjects | Animals Antigens, CD34 - immunology Bone marrow Graft vs Host Disease - immunology Hematopoietic Stem Cell Transplantation Histocompatibility - immunology HLA Antigens - immunology Humans Mice Nonmyeloablative conditioning T-Lymphocytes, Cytotoxic - immunology Tolerance Transplantation Immunology |
title | Crossing the HLA barriers |
url | http://sfxeu10.hosted.exlibrisgroup.com/loughborough?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-01-04T03%3A18%3A44IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_cross&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Crossing%20the%20HLA%20barriers&rft.jtitle=Blood%20cells,%20molecules,%20&%20diseases&rft.au=Reisner,%20Yair&rft.date=2004-11-01&rft.volume=33&rft.issue=3&rft.spage=206&rft.epage=210&rft.pages=206-210&rft.issn=1079-9796&rft.eissn=1096-0961&rft_id=info:doi/10.1016/j.bcmd.2004.08.004&rft_dat=%3Cproquest_cross%3E67044312%3C/proquest_cross%3E%3Cgrp_id%3Ecdi_FETCH-LOGICAL-c352t-eb46f92c6d00e8ec558ca08404ae5347c97045725fc5085af2d0226d93dbbadc3%3C/grp_id%3E%3Coa%3E%3C/oa%3E%3Curl%3E%3C/url%3E&rft_id=info:oai/&rft_pqid=67044312&rft_id=info:pmid/15528132&rfr_iscdi=true |